A previous study found that early intravenous indomethacin administration prolonged respiratory support in very low birth weight infants. We have, therefore, designed a randomized, doable blind controlled study to evaluate the oxygenation, and surfactant requirements in preterm low birth weight infants receiving early indomethacin administration.
Introduction
Patency of the ductus arteriosus (PDA) remains a significant problem in premature neonates. Current medical therapy usually involves the use of indomethacin, a prostaglandin synthetase inhibitor. However, even with early diagnosis and early closure of the PDA, these infants remain at risk for harmful effects of the silent left to right shunting in the interval between diagnosis and successful closure. 1 In an attempt to improve the efficacy of indomethacin therapy, early administration of indomethacin has been tried by several investigators with different protocols and conflicting results. 2 " 8 Indomethacin is known to have some undesirable effects, such as reduction of the cerebral blood flow, 9 prolongation of bleeding time, 4 and reduced renal blood flow. 4 Vincer et al. found that early intravenous indomethacin prolonged respiratory support in very low birth weight infants. 10 Several animal studies indicate that inhibitors of prostaglandin (PG) synthesis inhibits the secretion of endogenous surfactant that occurs with ventilation. 11 We designed a randomized, double-blind controlled study to evaluate the oxygenation and the requirement for surfactant administration in preterm low birth weight infants receiving early indomethacin administration.
Materials and Methods
This prospective, randomized study was performed in the neonatal intensive care unit (NICU) at Al Hada Military Hospital during the 15-month period from March 1993 to May 1994. The study protocol was approved by the local human ethics committee. Informed parental consent was obtained prior to study entry. Eligible neonates were those preterm infants weighing less than 1750 g admitted to the NICU before the age of 8 h who developed respiratory distress syndrome (RDS) severe enough
to require assisted ventilation with a fraction of inspired oxygen (FiO 2 ) >0.30 in order to achieve a PaO 2 of between 55 and 80 mmHg. The diagnosis of RDS also required radiographic confirmation.
The criteria for exclusion from the study included neonatal sepsis, death within 12 h of life, congenital anomalies, thrombocytopenia (platelet < 75000/ mm 3 ), hypercreatininaemia (creatinine > 180 /anol/1), hyperbilirubinaemia (serum indirect bilirubin > 90 /anol/1 in the first 8 h of life) or haemorrhage.
The surfactant preparation used was Survanta (Beractant, Ross Laboratories, Division of Abbott Laboratories, Columbus, OH). The assigned dose was delivered intratracheally as described by Hoekstra et al. u The first dose of Survanta should be given within the first 8 h of life.
Additional doses could be given from 6 to 48 h after birth at a minimum of 6 h intervals up to a maximum of four doses if the following criteria were met, 12 viz (a) continued intubation and mechanical ventilation because of RDS and (b) had a PaO 2 <80 mmHg in FiO 2 >0.30.
On admission and after obtaining parental consent, patients were randomized by sealed, sequentially numbered, and coded envelopes. The Indomethacin-treated group received a total of three doses of indomethacin of 0.2 mg/kg over 10 min at 24-hourly intervals starting at 12 h of age. The second group (control group) received an equal volume of saline placebo.
Perinatal data were obtained by maternal interviews and charts. Neonatal data were obtained from review of the medical record. Ventilator settings and arterial blood gases were recorded every 6 h for the first 48 h of life. The duration of mechanical ventilation (MV) were recorded and compared.
Oxygenation was assessed by FiO2 required, and a/ A PO 2 ratio where APO 2 = FiO2 (barometric pressure-47)-PaCO2/0:8.
PDA was considered clinically significant if a systolic or continuous heart murmur was associated with two or more of the following additional criteria: (a) bounding peripheral pulses, (b) hyperdynamic pulsation, (c) radiographic evidence suggestive of cardiomegaly or pulmonary oedema. Echocardiographic examinations were performed on all patients on postnatal days 1 (before starting treatment), 3 and 5 of life on day of study, and repeated later if there was evidence of continued patency. The initial evaluation included two-dimensional, M-mode, pulsed Doppler, and colour flow. Two-dimensional studies were performed for direct visualization of the PDA and left to right shunts were documented with pulsed Doppler echocardiography and colour flow mapping. Lntravcntricular haemorrhage (TVH) was graded according to the classification of Papile et a/. 13 Diagnosis being made by cranial ultrasonography performed on postnatal days 3 and 5. Cranial computerized axial tomography scan was carried out on all subjects prior to their discharge from N1CU. Bronchopulmonary dysplasia (BPD) was diagnosed according to a history of pulmonary disease requiring MV, with persistent radiographic abnormalities and the need of supplemental oxygen to prevent hypoxia on day 28. A neonate was considered to have necrotizing enterocolitis (NEC) if he or she exhibited characteristic clinical signs and there was supporting radiologic evidence.
14 Renal function was assessed on postnatal day 1, 3, and 5 by serum and urine Na, K, creatinine, creatinine clearance, and daily input/ output ratio. A daily complete blood count with platelet count and serum bilirubin were done. Duration of hospitalization was determined. The code was broken at the end of the entire study.
Statistical methods
The data pertaining to doses of surfactant, duration of hospitalization, duration of mechanical ventilation requirement, and supplemental oxygen administration were analysed using Wilcoxon Rank Sum Test. The difference in FiO2 and a/A PO2 ratio between the indomethacin and the control groups were analysed using analysis of variance (ANOVA). Comparison of the types of rates of complications between the two groups was assessed using the Fischer-exact-test. P values of <0.05 were considered significant.
Results
Five infants were excluded from this study (two congenital malformations, two very early deaths with documented septicemia and one where the consent was refused by the father). Twenty-seven infants with birth weight between 690 and 1750 g were enrolled in this trial. Fourteen patients were assigned to the early indomethacin group and thirteen to the control group. As shown in Table 1 , there were no significant differences in the birth weight, gestational age, caesarian birth, sex, or the Apgar scores.
At admission there was no significant difference between the two groups regarding FiO2 and a/AO 2 ratio ( Table 1 ). The control group exhibited a significant improvement in oxygenation (FiO 2 , a/AO 2 ) compared with the early indomethacin' group at 24 and 48 h of life ( Table 2 ). The number of doses of surfactant therapy was significantly higher in the early indomethacin group compared with the control group P = 0.02 ( Table 2 ). The duration of mechanical ventilation of the control group was not significantly shorter (median of 35.2 v. 44.8 h, P = 0.39). The total duration of oxygen therapy was not significantly different ( Table 2) . Two infants in the control group developed a detected PDA on postnatal day 3 and were treated by indomethacin (0.2 mg/kg/day for a total of three doses) resulting in successful ductal closure on postnatal day 5 for the first and day 45 for the second. In the early indomethacin group, a PDA was detected in two infants at the age of 1 day, but
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Vol. 43 February 1997 'Entries consist of mean (standard deviation). fFor sex, the number of male infants is listed. tApgar score is expressed as median (range). these had closed by postnatal day 3. Three infants in this group re-opened the ductus on postnatal days 5, 10, and 15, respectively. These closed on postnatal days 44, 20, and 90. All of these infants received indomethacin treatment. There was no significant differences in the incidence of NEC, BPD, IVH. The duration of hospitalization and mortality were similar between the two groups.
There was no significant difference in the daily input to output ratio, crcatinine clearance (Table 3) and platelet count.
Discussion
In this randomized study involving 27 infants, there was a significant alteration in the oxygenation (the decrease of a/APO2 and the increase of requirement) at 24 and 48 h after birth in the early indomethacin group compared with the control group. Also the requirement of surfactant was significantly larger in the early indomethacin group. Although it was not statistically significant, the duration of the mechanical ventilation was longer in the indomethacin group. Vincer et a/. 10 found that infants in the placebo group were weaned from the mechanical ventilation at an earlier age than infants in the early intravenous indomethacin group receiving 0.2 mg/kg/doses at 12, 24, and 36 h after birth. He explained his findings by a possible reduction in the pulmonary compliance due to oliguria secondary to indomethacin treatment. Our study was consistent with others, 6 ' 8 showing renal function was not significantly different between the two groups so the lack of improvement in the early indomethacin group could not be due to water retention. Indomethacin is a potent prostaglandin inhibitor. Several animal studies indicate that prostaglandins influence the secretion of surfactant. Inhibitors of prostaglandin synthesis abolish the increase in surfactant secretion that occurs with ventilation. 15 Marino et al} 6 found that indomethacin inhibits phosphatidylcholine secretion in slices of newborn rabbit lung. Based on these facts, we believe that early indomethacin administration could alter oxygenation and surfactant therapy in infants during the early phase of hyaline membrane disease by reduction of pulmonary surfactant secretion. The relative high dose of prophylactic indomethacin therapy (0.2 mg/kg) that we used in our patients possibly led to these undesirable respiratory effects. Strasser et al. 11 found that the fall of PGE2 levels in lung lavage fluid was significant when indomethacin 0.25 mg/kg was given. In contrast, when indomethacin was given in a reduced dose (0.1 mg/kg) only a slight effect on PGE2 synthesis could be seen. A second possible explanation of a/APOj alteration, that indomethacin may have an independent effect by decreasing pulmonary blood flow with consequent ventilationperfusion mismatch. 18 There was no significant difference between the two groups regarding the incidence of the BPD, duration of oxygen therapy, and the duration of hospitalization, leading us to believe that long term pulmonary function in the treated group was not affected by the short-term complications. Although the initial incidence of PDA was not different between the two groups, we can not explain the increased incidence of ductal reopening in the indomethacin group. Ramsey et al. demonstrated that even with an indomethacin serum level of 250 ng/ml the initial response to indomethacin treatment did not predict whether ductus arteriosus was going to reopen.
We did not find a difference between the two groups in the incidence of severe FVH (grades 3 and 4). Ment et al. s demonstrated that low dose prophylactic indomethacin (0.1 mg/kg/dose) for three doses at 24 h intervals significantly decreased the incidence and severity of FVH. The lack of difference in the incidence of IVH may have been related to our population sample size not being large enough to impart sufficient statistical power. Although early administration of indomethacin may be useful in reducing the risk of periventricular hemorrhage, indomethacin is associated with reduction in cerebral blood flow. Edwards et al. 20 have demonstrated by near-infra-red spectroscopy that large reductions in flow and oxygen delivery to the brain occur in neonates given indomethacin. According to these findings, a major theoretical concern is that by decreasing cerebral blood flow, indomethacin increase the risk of periventricular leukomalacia or other ischaemic lesions.
In conclusion, we have shown that early indomethacin (0.2 mg/kg) administered to low birth weight neonates significantly decreases oxygenation and increases the requirement for surfactant. Based on this study, we believe that the 0.2 mg/kg/dose of indomethacin should perhaps not be recommended as a prophylactic treatment. Further prospective randomized multicentre trials with a low dose prophylactic indomethacin should focus on the eventual pulmonary side-effects and the increased risk of periventricular leukomalacia.
